Founders & Leadership

  • Home
  • Founders & Leadership
Chairman

Ghulam Mustafa Jajjah

Voice Chairman

Dr. Zafar Mustafa Jajjah

MBBS (Κ.Ε), MBA

I have always envisioned MCOLSON Research Laboratories as future innovators of manufacturing technology and pioneers of Research & Development in pharmaceutical sector of Pakistan. The Dream started with inception of Dyson Research Laboratories manufacturing facility in 2005 and since then the appetite of our core vision has never met satiety. We continue to excel in our field with a team of specialists and they are keen in delivering to our community of what is expected from us as a national pharmaceutical concern. In this journey of becoming global from national, our untiring efforts will continue with the same zeal and fervor with which we initiated this organization.

Chief Executive Officer

Faysal Mustafa Jajjah

With over two decades of distinguished experience in the pharmaceutical industry, Faysal Mustafa Jajjah leads Demont Research Laboratories with a visionary approach and a relentless commitment to excellence. Holding an MBA with a specialization in pharmaceutical management, Mr. Jajjah brings a unique blend of strategic insight, operational expertise, and deep industry knowledge to the helm of the organization.Throughout his career, he has played a pivotal role in driving innovation, expanding global market reach, and fostering a culture of integrity and performance. Under his leadership, Demont has evolved into a cutting-edge pharmaceutical company known for its quality, compliance, and patient-centric approach. Mr. Jajjah’s strategic foresight was instrumental in the transformation of Garent Pharmaceuticals into Demont Research Laboratories, including the acquisition of a state-of-the-art manufacturing facility that now serves as the backbone of the company’s production capabilities. His leadership philosophy centers on empowering teams, embracing innovation, and delivering value to patients and stakeholders alike. As CEO, he continues to guide Demont’s growth trajectory, ensuring the company remains at the forefront of pharmaceutical advancement.